

Interim report Q2, 2021.

April - June 2021

- Net sales amounted to 33,5 MSEK (34,2).
- EBITDA equalled 4 MSEK (6,7).
- Operating profit (EBIT) is 1,2 MSEK (3,0)
- Profit after tax amounted to 0,75 MSEK (2,5)
- Earnings per share amounted to SEK 0,07 (0,25) per share

Year-to-date 2021

- Net sales amounted to 64 MSEK (73,0).
- EBITDA equalled 7,5 MSEK (9,5).
- Operating profit (EBIT) is 2,0 MSEK (3,2)
- Profit after tax amounted to 1,7 MSEK (2,8)
- Earnings per share amounted to SEK 0,16 (0,29) per share

Events during the period

- The acquisition of PharmaCept GmbH was performed in June 2021
- Purchase price allocation is preliminary and will be presented in later report.

Events after the period

- The formalities of the registration of the PharmaCept GmbH purchase agreement were completed in Germany.
- A new patent has been filed covering a combination of the technology-platform with mRNA in the field of bone repair and healing.

Key financial indicators

	April-June 2021	April-June 2020	Jan-June 2021	Jan-June 2020	Jan-Dec 2020
Net sales, TSEK	33 535	34 263	63 964	73 057	142 337
EBITDA, TSEK	4 013	6 694	7 551	9 548	16 193
EBITDA margin, %	12%	20%	12%	13%	11%
Operating profit, TSEK	1 226	3 049	2 010	3 235	4 526
Net profit/loss for the period, TSEK	756	2 483	1 761	2 893	1 819
Earnings per share, SEK*	0,07	0,25	0,09	0,29	0,24
Operating cash flow, TSEK	11 608	-4 532	15 296	3 092	-5 545
Operating cash flow per share, SEK	1,07	-0,45	1,42	0	-0,54
Equity ratio, %	66%	59%	66%	59%	58,8%
Equity at period end, TSEK	138 027	116 223	138 027	116 223	116 121
Net debt, TSEK	-20 814	-31 432	-20 814	-31 432	-33 902

*Based on the average numbers of shares. See page 9

CEO COMMENT.

The second quarter continued to show recovery to pre-COVID business levels, and we have started seeing growth in the CDMO segment as customers clinical programs are rescheduled and planned. Once again, I have been impressed by our high working capacity helping us meet our customer's needs. Our technology product pipeline continues to grow



CDMO Operations

During the second quarter, our business development team signed new orders for two new development projects with new and existing customers, including a new process development customer and a new manufacturing project with an existing customer. While we are always pleased to add new companies to our customer list, we are equally happy to expand our relationships with existing customers as their needs grow. Additionally, our manufacturing team completed a new drug validation program for a contract manufacturing customer, resulting in a long-term commercial manufacturing agreement. Finally, our operational teams met all orders on time towards the end of the second quarter as we prepared to initiate our scheduled annual preventative maintenance shutdown at the beginning of July.

PharmaCept

The second quarter marked the closing of the deal with PharmaCept GmbH. We have made strategic acquisitions over the years. Still, PharmaCept is potentially highly transformative. The combination of PharmaCept's expertise to the existing research, development manufacturing teams means we can potentially cover the entire supply chain and significantly reduce time to market on future products developed on our technology platform. We will undertake the integration work and synergy realization in the second half of 2021.

Technology Products

The effect of the COVID pandemic on technology-based products has caused a slowdown in sales and impacted our

planned timetable for the market introduction of SmartGel and SmartPAN®. However, we are starting to see increased demand from primary clinics and hospitals in Europe for EmboCept® S and PlatiCept®. We are also driving regulatory filings of all our technology-based products in secondary markets focusing on Latin America, the Asia Pacific and Russia. Our research and development activities remain on target and running accordingly.

Technology Royalties

Lower license revenues were received from Becton Dickinson through a slowdown in demand due to the COVID pandemic and a negative currency effect against a weaker USD exchange rate. However, revenues remain in line with the expectations for the period, and our diversified business model related to our revenue streams off-sets the negative impact of the lower licence revenues.

Concluding Remarks

Our second-quarter performance demonstrates the strength of our strategy and diversified business model related to our revenue streams. Whilst we plan to continue this trend, we also aim to increase our investment in sales and marketing and expanding our geographic reach to support our financial target of having twenty five percent of revenue generated through our technology products in the future over the remainder of 2021 and into 2022.

Justin Pierce (CEO)



Manufacturing.

Magle Chemoswed provides manufacturing services to support the sale of generic drug substances owned by the company and the manufacturing of clinical trial materials and commercial supply on a contract manufacturing basis for customers. Magle Chemoswed manufactures and operates under Good Manufacturing Practices and ISO guidelines.

Second quarter manufacturing revenues were led by an increased demand in the clinical material and medical device areas alongside supply of technology-based products. Combined revenues for the period were 18,94 MSEK (12,18). An upscale and validation program for two separate customers have contributed to the increased sales year-on-year.

For the quarter, cost of product sales and contract manufacturing services increased to 4,94 MSEK (3,20). The increase primarily consists of an increase in costs

associated with our contract manufacturing services due to higher volume of CDMO manufacturing.

Sales for the year to date are 33,54 MSEK (34,26) a decrease in sales of 2%. Adjusted for currencies revenues increased 8%. For the year-to-date, cost of product sales and contract manufacturing services decreased to 8,86 MSEK (16,83). The decrease primarily consists of the change to cost of goods sold calculations completed in 2020.

Additionally, new suppliers and reduced cost supply agreements entered in 2020 are having a positive impact on the cost of sales.

CMO pharma, YTD

↑ 1%
SEK30,83 million

Cost of sales, YTD

↓ 47%
SEK8.8 million

CMO medical devices, YTD

↓ 19%
SEK2,44 million



Services.

We have a highly experienced and flexible team dedicated to our service offerings. We offer a full range of development services covering the development chain for pharmaceuticals and medical devices. With over 70 years of combined experience, we have a rich history in successfully providing development services.

Contract development service revenues for the period were 9,46 MSEK (7,57). An increased demand for analytic chemistry and solid-state services have added to increased revenues in the services area of the business. A higher level of contract development customers has added to the remainder of the increased revenues.


Additionally, during the quarter the Company has undertaken capital investment amounting to 1,5 MSEK to increase the service offerings that is expected to lead to a return on investment within 12 months.

Sales for the year to date are 19,26 MSEK (20,44) a decrease in sales of 6%. Adjusted for currencies revenues increased 2% over the year.


Two additional development projects have been signed commencing in the second and third quarters of 2021.

There remains scope of demand to increase sales of services in the future and we are investing in staff to increase throughput of customer requests.

Services revenues (SEK '000)



We continue to see growth and demand in the development and analytic services on the CDMO side of the business. New requests for proposals are at a high level in 2021.



Technology platform pipeline.

Our technology base is microporous polysaccharide microspheres, derived from purified plant starch transformed through a unique chemical process developed in-house, which allows the control of microsphere size from 10 µm to 2000 µm. The microspheres are naturally bioabsorbable and biodegradable.

Advanced wound care

Based on patented technology, we develop products to combat and control infection in serious wounds.

	Phase 1 Ideation	Phase 2 Concept	Phase 3 Design & Development	Phase 4 Design Verification	Phase 5 Approval
SmartGEL I					
SmartGEL II					

Surgical and diagnostics

Based on our owned technology, we help surgeons save lives by providing biodegradable solutions for use during surgery.

	Phase 1 Ideation	Phase 2 Concept	Phase 3 Design & Development	Phase 4 Design Verification	Phase 5 Approval
SmartPAN					
SmartBONE					

Embolisation

We develop vascular embolization devices using our technology platform as embolic agents to restrict the blood flow to a targeted area.

	Phase 1 Ideation	Phase 2 Concept	Phase 3 Design & Development	Phase 4 Design Verification	Phase 5 Approval
EmboCept M					
EmboCept L					



Medical devices and royalties.

We have a dedicated and highly experienced research and development team that is supported through the integration of the services we offer as a company. Our development is expedited due to our ability to develop in parallel with analytic, formulation and manufacturing expertise.

Our planned post-market studies for SmartGel with our partner in Russia is running according to our adjusted schedule and is expected to commence in 2022. We have received the first forecast and are preparing to manufacture in late 2021. We have entered into an agreement with a distribution partner for the marketing of SmartGel in Latin America.

Our SmartPAN® product is in the final stages of reimbursement applications and the first post-market clinical study is planned to take place at Heidelberg University Hospital with an expected start date late Q4, 2021 or early Q1, 2022.

Our vascular embolisation product sales have been impacted because of the COVID pandemic and some signs of recovery in Europe are being seen in late Q2 and early Q3, 2021. We have commenced marketing and regulatory registration work in several territories including South Korea, Japan and Latin America to increase the geographic market access and the global market share for the product.

Technology Royalties

Technology royalties in the quarter amounted to 3,63 MSEK (13,13). The decline in royalty revenues is a direct result of the effect of the COVID pandemic leading to reduced number of non-essential surgical procedures in the United States and Europe. The slowdown in surgical procedures has resulted in a reduced sale of units in the main territories. Technology royalties for the year-to-date is 11,39 MSEK (19,49) a decrease to date of 42%. Adjusted for currencies revenues decreased 33% over the year.



The addition of PharmaCept is an excellent opportunity for the faster introduction of new technology products to the market in the future.

- Justin Pierce



Financial overview Q2, 2021.

net sales

Net sales in the period amounted to 33,53 MSEK (34,26) a period decrease of 2%. The CDMO manufacturing revenues increased by 55% to 18,9 MSEK (12,2). Sales in CDMO services increased by 25% to 9,4 MSEK (7,5). Medical device sales were at 1,4 MSEK (1,3). The technology royalties for the period were 3,6 MSEK (13,1).

raw materials and consumables

Raw materials and consumables amounted to 4,9 MSEK (3,2), which resulted in a gross margin of 85% (91%).

other external expenses

Other external expenses amounted to 11,3 MSEK (13,3).

personnel costs

Staff costs totaled to 16,1 MSEK (13,6). Personnel costs increased by 5% due to the collective agreement salary increases.

other operating income, expenses

Other operating income and expenses consisted mainly of exchange gains and losses on operating assets and liabilities and government founded projects and contribution for employees. Other operating income amounted to 0 MSEK (0 and other operating expenses amounted to SEK 0 (0) for the quarter.

operating result

Operating profit amounted to 1,2 MSEK (3,0).

net financial items

Net financial items amounted to -0,25 MSEK (0,13).

net profit/loss for period

Net profit amounted to 0,75 MSEK (2,48), which corresponds to earnings per share of SEK 0,07

Financial Position	Jan-June 2021	Jan-June 2020	Jan-Dec 2020
TSEK			
Cash & cash equivalents	12 185	2 386	6 122
Interest-bearing debt	32 999	33 818	40 399
Net debt	-20 814	-31 432	-34 277
Equity	138 027	116 223	115 407

Cashflow	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
TSEK					
Operations	11 608	-4 531	15 297	3 092	12 296
Investing activities	-18 608	-4 694	-21 611	-6 609	-6 583
Financing activities	-4 829	8 928	12 377	2 609	-3 271

Condensed consolidated income statement.

	Jan-Mar. 2021	Jan-Mar. 2020	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
TSEK							
Revenues							
Net sales	30 429	38 793	33 535	34 263	63 964	73 056	142 337
Other revenues	966	2 569	2 941	2 642	3 907	5 210	3 914
Total	31 396	41 362	36 476	36 905	67 872	78 267	146 252
Raw materials and consumables	-3 912	-13 627	-4 948	-3 208	-8 860	-16 835	-30 395
Other external expenses	-8 943	-8 296	-11 328	-13 320	-20 270	-21 617	-40 801,4
Personnel costs	-15 003	-16 584	-16 188	-13 683	-31 190	-30 267	-58 859
Depreciation and amortization	-2 754	-2 668	-2 787	-3 645	-5 542	-6 313	-11 667
Other operating expenses	-	-	-	-	-	-	-3
Total operating expenses	-30 612	-41 175	-35 251	-33 856	-65 862	-75 032	-141 726
Operating profit/loss	784	187	1 226	3 049	2 010	3 235	4 526
Profit/loss from financial items							
Financial income	-	443	-	264	-	706	706
Financial expenses	496	-92	-257	-137	239	-228	-2798
Profit before tax	1 280	538	968	3 175	2 248	3 713	2 434
Taxes for the period	-276	-128	-212	-692	-488	-820	-614
Net profit/loss for the period	1 004	410	756	2 483	1 761	2 893	1 819

Condensed consolidated statement of comprehensive income.

	Jan-Mar. 2021	Jan-Mar. 2020	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
TSEK							
Profit/loss for the period	1 004	410	756	2 483	1 761	2 893	1 819
Total comprehensive income for the period	1 004	410	756	2 483	1 761	2 893	1 819

Earnings per share.

	Jan-Mar. 2021	Jan-Mar. 2020	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
Equity holders of the parent							
Earnings per share before dilution, share issue	0,10	0,82	0,08	4,97	0,10	5,79	3,64
Earnings per share after dilution*, share issue**	0,09	0,75	0,07	0,47	0,09	0,29	0,24
Profit/loss for the period	1 004	410	756	2 483	1 004	2 893	1 819
Average number of shares before dilution, share issue	10 000	500	10 000	500	10 000	500	500
Average number of shares after dilution, share issue	10 655	500	10 800	5 246	10 787	10 000	7 671

*A share split was carried out on the 27th of March 2020, **A share issue was carried out on the 4th of January 2021

Condensed consolidated balance sheet.

	Jan-June 2021	Jan-June 2020	Jan-Dec 2020
TSEK			
ASSETS			
Intangible assets	45 644	27 427	28 966
Tangible assets	101 165	104 827	104 029
Deferred tax asset	-	-	2
Other non-current assets	55	55	55
Total non-current assets	146 864	132 309	133 052
Inventories	18 364	17 756	18 348
Trade receivables	21 786	22 572	26 271
Other operating receivables	11 012	20 920	14 272
Cash and cash equivalents	12 185	2 386	6 122
Total current assets	63 346	63 634	65 013
TOTAL ASSETS	210 210	195 943	198 065
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent	138 027	116 223	116 121
Liabilities to credit institutions	27 438	28 938	28 938
Leasing debt	2 543	4 114	3 302
Deferred tax liability	2 135	2 087	2 087
Total non-current liabilities	32 115	35 139	34 326
Liabilities to credit institutions	5 561	4 880	11 086
Leasing debt	1 510	1 513	1 494
Trade payables	14 206	9 544	12 365
Other operating liabilities	18 790	28 644	22 672
Total current liabilities	40 068	44 581	47 617
TOTAL EQUITY AND LIABILITIES	210 210	195 943	198 065

Condensed consolidated statement of changes in equity.

	Share capital	Other paid in capital	Translation reserves	Retained earnings incl. P/L for year	Total equity
TSEK					
As at 1 January 2020	50	98 927	-	14 682	113 659
Profit/loss as at 31 December 2020	-	-	-	1 819	1 819
Share issue	450	-	-	-450	-
Other comprehensive income as 31 December 2020	-	-	-	643	643
Equity as at 31 December 2020	500	98 927	-	16 694	116 121
As at 1 January 2021	500	98 927	-	16 694	116 121
Profit/loss as at 30 June 2021	-	-	-	1 761	1 761
Other comprehensive income as at 30 June 2021: Translation difference	-	-	146	-	146
Share issue	-	-	-	20 000	20 000
Equity as at 30 June 2021	500	98 927	146	38 455	138 028

Condensed consolidated statement of cash flows.

	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
TSEK					
Operating profit/loss	1 226	3 049	2 010	3 235	4 526
Adjustments for depreciation, amortisation and other non-cash items:	1 164	6 243	2 707	7 784	8 610
Changes in working capital	9 218	-13 824	10 580	-7 930	-19 910
Net cash flow from operating activities	11 608	-4 532	15 296	3 089	-6 775
Payment of Acquisition of subsidiary company	-17 674	-	-19 164	-	-5 904
Investments in assets	-934	-4 694	-2 447	-6 609	-7 948
Net cash flows from investing activities	-18 608	-4 694	-21 611	-6 609	-13 852
Debt incurred	0	28 206	0	27 062	25 313
Amortisation of bank loan	-750	0	-750	-5 940	-1 125
Repayment to Shareholder	0	-16 000	0	-16 000	0
Amortisation of leasing	-373	-441	-743	-820	-2 100
Change in bank overdraft	-3 707	-3 269	-6 275	-2 124	721
Shareholders contribution	0	431	20 145	431	646
Net cash flow from financing activities	-4 829	8 927	12 377	2 609	23 455
Net cash flow	-11 829	-301	6 062	-911	2 828
Cash and cash equivalents at beginning of period	24 014	2 684	6 122	3 294	3 294
Cash and cash equivalents at end of period	12 185	2 383	12 185	2 383	6 122

Parent company income statement.

	April-June 2021	April-June 2020	Jan-June 2021	Jan-June 2020	Jan-Dec 2020
TSEK					
Net sales	-	-	-	-	1 186
Intercompany revenue	1 106	-	2 600	-	-
Other revenues	-	1100	-	1 173	1 173
Total	1 106	1 100	2 600	1 173	2 359
Other external expenses	-1 103	-1617	-2 916	-1769	-3924
Personnel costs	-40	-5	-41	-1 159	-1 203
Depreciation and amortization	-	0	-	0	0
Other operating expenses	-	-	-	-	0
Operating profit/loss	-37	-522	-357	-1 755	-2 768
Net financial items	-82	-4	214	-11,4	-375
Profit loss after financial items	-118	-526	-144	-1 766	-3 143
Appropriations	-	-	-	-	-
Taxes for the period	24	0	30	0	3 033
Net profit/loss for the period	-94	-526	-114	-1 766	-110

Parent company balance sheet.

	Jan.-June 2021	Jan.-June 2 020	Jan.-Dec. 2020
TSEK			
ASSETS			
Non-current assets	60 830	44 647	44 647
Other receivables	46 505	38 277	45 636
Prepaid expenses	123	35	33
Cash and cash equivalents	-4 811	537	-
TOTAL ASSETS	102 647	83 496	90 316
EQUITY AND LIABILITIES			
Equity			
Restricted equity	500	500	500
Unrestricted equity	91 252	69 495	71 366
Total equity	91 752	69 995	71 866
Current liabilities	10 895	13 501	18 451
TOTAL EQUITY AND LIABILITIES	102 647	83 496	90 316

note 1

GENERAL INFORMATION, ACCOUNTING PRINCIPLES

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The parent company's reporting has been prepared in accordance with RFR 2, Reporting for Legal Entities, and the Swedish Annual Accounts Act. Accounting principles have been applied as reported for the Annual Report per 31 December 2019. New or amended standards or interpretations of standards effective as of 31 March 2021 have not had any significant impact on Magle Chemoswed's financial statements.

note 2

SIGNIFICANT RISKS AND UNCERTAINTIES

The Group is exposed to various financial risks. The business is impacted by many factors that could affect the Group's result and financial position. It is Magle Chemoswed's strategy to continuously identify and manage risks. Financial risk management is described in the Prospectus.

note 3

TRANSACTIONS WITH RELATED PARTIES

The financial reports include costs related to the following transactions between Magle Chemoswed and related parties.

note 4

FINANCIAL ASSETS AND LIABILITIES

Fair values of current financial assets and liabilities are assessed agree with values accounted for.

note 5

SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function responsible for allocating resources and assessing the performance of the operating segments. In the Magle Chemoswed Group, the CEO has been identified as the chief operating decision maker who evaluates the Group's financial position and performance and makes strategic decisions. The CEO analyzes and monitors the business performance based on the Group as a whole. The assessment is thus that the Group's operations consist of one operating segment.

By nature of income	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec. 2020
TSEK					
API revenues (Manufacturing page 3)	18 936	12 181	30 830	30 053	72 513
Services revenues (Services page 4)	9 469	7 571	19 263	20 441	35 780
Medical device (Manufacturing page 3)	1 498	1 376	2 477	3 073	3 087
License revenues (Technology Product and Royalty page 5)	3 632	13 135	11 395	19 490	30 957
Total	33 535	34 263	63 964	73 057	142 337

By country	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec. 2020
TSEK					
Sweden	1 954	1 105	8 416	5 476	23 960
Europe excluding Sweden	12 468	13 111	28 530	27 905	37 717
Other territories	19 113	20 047	27 018	39 676	80 660
Total	33 535	34 263	63 964	73 057	142 337

By company	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec. 2020
TSEK					
Magle Chemoswed AB	33 039	33 385	62 552	70 650	137 849
Magle Chemoswed Holding AB	0		0		0
Adroit Science AB*	496	878	1 413	2 407	4 488
Total	33 535	34 263	63 964	73 057	142 337



Definitions.

Magle Chemoswed uses Alternative Performance Measures (APM) to enhance understandability of the information in the financial reports, both for external analysis and comparison and internal performance assessment.

Alternative Performance Measures are key figures not defined in financial reports prepared according to IFRS. The following key figures are used:

sales growth

The difference in net sales between two periods in relation to net sales for the earlier period. Shows the operations sales performance.

interest bearing debt

Borrowings from banks, financial institutions and lease liabilities, short and long term. Shows the debt level of the group and forms the base for interest expenses.

net debt

Interest bearing debt minus cash and cash equivalents. Shows the group's net debt and is used to measure the leverage level of the group and future funding needs.

Sales Growth	Apr-Jun 2021	Apr-Jun 2020	Jan-June 2021	Jan-June 2020	Jan-Dec. 2020
Net sales, TSEK	33 535	34 263	63 964	73 057	142 337
Sales growth, %	-2%	0%	-14%	0%	10%
Gross profit, TSEK	28 587	31 275	55 105	56 253	111 942
Gross margin, %	85%	91%	86%	77%	79%

Indicators	Apr-Jun 2021	Apr-Jun 2020	Jan-June 2021	Jan-June 2020	Jan-Dec. 2020
Non-current borrowings, TSEK	27 438	28 938	27 438	28 938	28 938
Current borrowings, TSEK	5 561	4 880	5 561	4 880	11 086
Interest bearing debt, TSEK	32 999	33 818	32 999	33 818	40 024
Cash and cash equivalents, TSEK	12 185	2 386	12 185	2 386	6 122
Net debt, TSEK	-20 814	-31 432	-20 814	-31 432	-33 902

note 6

NUMBER OF SHARES

Ordinary Shares	Number of shares	Potential shares
31 December 2019	500	
30 June 2020	10 000 000	225 000
4 January 2021	10 800 000	225 000

Share split was made on 27th of March 2020, share issue on 4th of January 2021.

note 7

WARRANTS

At period end, there is one warrant program. The warrant program was executed in 2020. Warrants give the holder the right to acquire 1 ordinary share.

Warrant program	Number of options	Equals number of shares
Balance January 1, 2020	0	
Balance March 30, 2020	0	
Balance June 30, 2020	225 000	225 000
Balance December 31, 2020	225 000	225 000

DECLARATION OF THE BOARD OF DIRECTORS AND THE CEO

The undersigned Board members assure that this Interim report provides a true and fair view of the development of the Group's and Parent Company's operations, position and performance as well as describing material risks and uncertainties faced by the companies being part of the Group. This interim report has not been reviewed by the Company's auditors.



Hans Henrik Lidgard (Chair)



Sven Christer Nilsson



Mats Pettersson



Malin Malmstö



Hedda Lidgard



Joel Eklund



Justin Pierce (CEO)



Ingela Fritzson

Malmö August 17, 2021

This information is information that Magle Chemoswed Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above 2021-08-17, at. 08.00.

FORTHCOMING DISCLOSURES OF INFORMATION

FINANCIAL CALENDAR

DATE

INTERIM REPORT Q3, 2021	16TH NOVEMBER, 2021
FULL-YEAR AND INTERIM REPORT Q4, 2021	25TH FEBRUARY, 2021

CONTACT INFORMATION

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.